Cryoskin? export licence award

RNS Number : 4140S

Ilika plc

21 November 2011

 



Ilika plc

("Ilika" or the "Company")

 

 Cryoskin® export licence award

Ilika plc (AIM:IKA), the advanced cleantech and biomedical materials discovery company, announces that its subsidiary, Altrika Limited ("Altrika"), has been awarded a Full Manufacturer/Importer's Licence (MIA) by the UK Medicines and Healthcare products Regulatory Agency (MHRA). This licence will enable Altrika to export its leading allogeneic skin cell product, Cryoskin®, to global markets outside the EU where there is a significant need to treat burns and other serious skin wounds.

"The Manufacturer's Licence is recognition by the UK's statutory regulatory body of the standards we maintain at Altrika to ensure the quality of our medicinal products," said Altrika CEO, Graeme Purdy. "We are committed to providing the best possible treatment for clinicians and their patients to alleviate the pain, infection risk and long term problems associated with severe skin wounds. This is a tremendous demonstration of that commitment. In addition, the licence underpins our ability to ramp up sales of Cryoskin® in support of our revenue projections in 2012 and beyond."

Cryoskin® comprises sub-confluent cultured allogeneic keratinocytes which are presented on a patented polymer dressing for easy application to skin wounds. Used alone, or in combination with other therapies, it has demonstrated tangible improvement in the speed of recovery of wounds and the subsequent quality of the regenerated skin.

Cryoskin® is currently available on a specific patient basis for treating burn injuries in the UK. More information on Cryoskin® and Altrika's complementary autologous skin cell treatment, Myskin®, can be found at www.altrika.com.

 

For more information contact:

Ilika plc	www.ilika.com
Graeme Purdy, Chief Executive	Tel: [phone]
Steve Boydell, Finance Director
Nomura Code Securities Limited (NOMAD)	Tel: [phone]
Phil Walker / Christopher Golden
Walbrook PR Ltd	Tel: [phone]
Paul McManus	Mob: [phone] or [e-mail]
Paul Cornelius	Mob: [phone] or [e-mail]

 

About Ilika

Ilika (AIM: IKA) is an advanced materials company which accelerates the discovery of new and patentable materials using its unique high throughput technologies (''HTT'') process for identified end uses in the energy, electronics and biomedical sectors. This process enables hundreds of scalable materials to be made in a single, automated operation and subsequently tested for key properties.

Traditionally, materials development has been a slow and arduous task, with manual, sequential methods used to make samples of material that are then tested for suitability. On average, it takes between seven and 10 years to move from an initial discovery through to the first commercial prototype. Experiments carried out by the Company can be executed 10 to 100 times faster than using traditional techniques.

The Company focuses on three principal sectors and has a number of active development programmes addressing markets within each sector:

Energy - developing innovative new materials for Lithium-ion batteries for vehicles for Toyota; developing high capacity hydrogen storage materials with Shell Hydrogen and Johnson Matthey through joint development programmes; developing cheaper alternatives to Platinum electrodes for use in fuel cells through a grant-funded project with the Carbon Trust; developing new materials for use in fuel cells for the transport sector for a major vehicle manufacturer; and carrying out in-house research on film photovoltaic solar cells.

Electronics - developing lead-free piezoelectric materials through a joint development programme with CeramTec; and developing phase change memory materials for high capacity memory.

Biomedical - developing polymers to enable the filtering of somatic stem cells from blood with a major global supplier of filters; it has been selling its CryoSkin® and MySkin® products for the treatment of burns and wounds in the UK through a specialist distributor and intends to commence clinical trials of its corneal bandage candidate.

The Group's commercialisation strategy is to enter into joint development or licensing agreements with large multinational companies which are seeking to commercialise products developed using the intellectual property created through jointly-funded programmes. Current commercialisation partners include large multinational companies such as Toyota, Shell, Johnson Matthey and CeramTec. The Company generates revenues from three sources: licensing and milestone payments from joint development programmes; fee for service from contract research projects; and from sales of CryoSkin® and MySkin®.

Further information can be found at www.ilika.com

 

END

 

 

NRAEAXFPFSXFFFF